A new review highlights the potential role of single nucleotide polymorphisms (SNPs) in improving the early diagnosis and targeted intervention of coronary microvascular dysfunction (CMD)—a condition linked to myocardial ischemia despite the absence of major artery blockages.
Astellas places new bet on gene therapy in $50M upfront deal with UK startup
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS